Merck KGaA has agreed to acquire Silence Therapeutics for approximately $1.3 billion in equity value, offering $20 per ADS. The transaction centers on divesiran, an RNA interference therapy that achieved an 88% response rate in Phase 2 polycythemia vera testing.
PharmaEssentia will present six studies examining treatment gaps and real-world BESREMi use in essential thrombocythemia and polycythemia vera. The findings include 55% two-year treatment persistence in first-line PV users and new molecular response data from Asian patient populations.
Silence Therapeutics raises $175 million after positive divesiran Phase 2 data, strengthening funding ahead of a planned Phase 3 PV trial.
Silence Therapeutics will reveal Phase 2 SANRECO divesiran results in polycythemia vera, testing hematocrit control and phlebotomy reduction.
Read how Health Canada’s BESREMi approval could reshape polycythemia vera treatment, reimbursement and PharmaEssentia’s Canadian strategy.
FDA approval brings BESREMi Pen to U.S. polycythemia vera care. Find out how convenience, safety and access may shape adoption.
PharmaEssentia’s ET data arrive before a key FDA date. Ropeginterferon could shift timing, sequencing, and risk thinking in MPN care.
Jakafi is mature, but dosing still matters. Incyte’s Jakafi XR approval could extend ruxolitinib’s strategic life in hematology.
PharmaEssentia’s Puerto Rico facility could reshape BESREMi supply resilience and U.S. expansion. Read what this means for biologics strategy.
AN2 Therapeutics plans a Phase 2 trial of epetraborole for polycythemia vera. Explore what this strategy could mean for future hematology treatments.